| Name | Title | Contact Details |
|---|
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We are currently evaluating apitegromab in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA. Positive six-month interim analysis results were announced in October 2020 and top-line data for the full 12-month treatment period are anticipated in the second quarter of 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a highly specific inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.
Regional Clinical Research is a Endicott, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rapid Micro Biosystems accelerates the detection of microbial contamination in the manufacture of pharmaceuticals, biologics, medical devices, and personal care products. The company`s Growth Direct™ Platform—the first and only growth-based platform to fully automate traditional microbial testing—detects contamination more quickly, delivering compelling economic benefits while improving quality control processes. The Growth Direct platform replaces slow, error-prone, manual processes, allowing manufacturers to accelerate timelines, maximize capacity, and reduce operational risk and downtime, all while maintaining the highest standards of data integrity. Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality products for improved patient outcomes. Rapid Micro Biosystems is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands.
AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients.
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.